CTNNB1 and Alzheimer disease: Thus, stimulating Wnt/beta-catenin signaling could represent a promising therapeutic target for human AD treatment, since its activation protects neurons against Abeta toxicity, the hallmark of the disease (Mao et al., 2001; Alvarez et al., 2004; Boonen et al., 2009; Fiorentini et al., 2010; Shruster et al., 2011; Zhang et al., 2011; Inestrosa et al., 2012, 2015).